J&P Medi (CEO Jeong Gwon-ho) , an AI platform-based bio-clinical full-cycle innovation company, announced last month that it signed a memorandum of understanding (MOU) with Yonsei University Biohealth Technology Holdings (CEO Song Young-goo) to support technology-based biohealth startups entering the clinical stage.
This agreement aims to establish a collaborative system centered on clinical execution, enabling promising biohealth companies discovered by the technology holding company to smoothly enter the clinical trial phase and subsequently lead to commercialization. As a contract research organization (CRO), J&P Medi will directly handle clinical trial design and operations, supporting the companies in advancing their clinical strategies.
Under the agreement, Yonsei University Biohealth Technology Holdings will select and recommend companies with technological prowess and growth potential, while J&P Medi will operate a special support program for these companies, including preferential CRO services and a dedicated A-team. The company plans to provide consulting services throughout the entire clinical and regulatory process, covering everything from strategy development and IND preparation to clinical operations, as well as preclinical and clinical design, regulatory strategy, and product approval roadmaps. This will reduce trial and error for start-up companies and enhance clinical execution efficiency.
The two organizations plan to establish a permanent collaboration channel to continuously share their clinical experience with promising companies and jointly enhance their pipeline from a clinical and growth strategy perspective. Furthermore, J&P Medi will collaborate with a fund established by Yonsei University Biohealth Technology Holdings, continuing a long-term partnership focused on clinical strategy.
Jeong Gwon-ho, CEO of JNP Medi, said that this agreement is significant in that it allows technology-based companies to secure practical execution capabilities in the clinical stage, and that the company will strengthen its role as a CRO partner that accompanies the entire process from clinical strategy establishment to operation.
- See more related articles
You must be logged in to post a comment.